Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (20,520,131)	$ (39,171,152)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash consideration for acquired in-process research and development	6,541,485
Impairment charges	1,000,000	24,940,687
Stock-based compensation	1,264,231	773,248
Depreciation	239,821	218,717
Amortization	147,500	83,652
Unrealized (gain) loss on foreign currency exchange	(5,761)	64,806
Debt discount accretion		180,611
Gain from disposal of property and equipment		(3,806)
Changes in fair value of warrant liability	(30,000)	2,878,484
Changes in fair value of embedded derivative		(184,555)
Changes in operating assets and liabilities:
Accounts receivable	2,440,759	344,301
Prepaid expenses and other current assets	133,001	499,391
Accounts payable	(354,628)	243,062
Accrued expenses and other current liabilities	(626,193)	17,110
Deferred revenue	22,032	(19,780)
Deferred rent		818,893
Lease obligation	(175,490)
Tax refund receivable	379,877	5,077,217
Deferred tax benefit	(58,500)	(6,149,794)
Net cash used in operating activities	(9,601,997)	(9,388,908)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for short-term investments	(28,257,379)
Purchases of property and equipment	(1,227)	(975,407)
Proceeds from sale of property and equipment		14,492
Additions to intangible assets	(27,772)	(40,227)
Net cash used in investing activities	(28,286,378)	(1,001,142)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of notes payable	(292,002)	(1,549,702)
Redemption of preferred stock		(2,386,285)
Cash paid in conjunction with warrant exchange	(25,000)	(1,100,000)
Proceeds from conditional economic incentive	150,000	100,000
Proceeds from issuance of common stock, net of issuance costs		4,334,816
Proceeds from issuance of common units, net of issuance costs	12,668,784	33,068,178
Proceeds from exercise of warrants and stock options	30,324	22,898
Net cash provided by financing activities	12,532,106	32,489,905
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		(50,365)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(25,356,269)	22,049,490
Cash, cash equivalents, and restricted cash — beginning of year	34,353,129	12,303,639
Cash, cash equivalents, and restricted cash — end of year	8,996,860	34,353,129
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest		57,214
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Common Stock issued for acquired in-process research and development	$ 3,791,485
Settlement of warrant liability for common stock		3,345,030
Notes payable issued in conjunction with the exchange of warrants		1,500,000
Series B Redeemable Convertible Preferred Stock [Member]
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Conversion of Series B redeemable convertible preferred stock into common stock		9,790,367
Accretion of Series B redeemable convertible preferred stock		$ 2,894,885